Thermo Fisher Scientific Life Sciences Solutions — Consolidated revenues increased by 8.4% to $2.59B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 8.4%, from $2.39B to $2.59B. This is a positive signal — higher values indicate stronger performance for this metric.
An increase reflects strong market demand and successful product adoption, while a decrease signals market saturation or competitive pressure.
The total gross income generated by the Life Sciences Solutions segment from the sale of reagents, instruments, and cons...
Standard top-line metric used across all public companies to measure segment scale.
tmo_segment_life_sciences_solutions_consolidated_revenues| Q2 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $3.56B | $4.23B | $3.29B | $2.49B | $2.49B | $2.49B | $2.49B | $2.39B | $2.59B |
| QoQ Change | — | +18.9% | -22.2% | -24.2% | +0.0% | +0.0% | +0.0% | -4.3% | +8.4% |
| YoY Change | — | — | -7.5% | -41.0% | -24.2% | — | — | -4.3% | +8.4% |
We use cookies for analytics. See our Privacy and Cookie Policy.